Advertisement
Screener

EMERGENT BIOSOLUTIONS INC. (EBS) Material Contracts

EMERGENT BIOSOLUTIONS INC. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

  • 2026-09-01: Form 8-K; Exhibit 10.1; Description Modification No. 21, effective August 18, 2026 to the BARDA AV7909 Contract.
  • 2026-08-06: Form 10-Q; Exhibit 10.9; Description Modification No. 15, effective June 26, 2026, to the ACAM2000 Contract (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on June 29, 2026).
  • 2026-08-06: Form 10-Q; Exhibit 10.8; Description Modification No. 2, effective May 18, 2026, to the BioThrax IDIQ Contract..
  • 2026-08-06: Form 10-Q; Exhibit 10.7; Description Modification No. 2, effective March 4, 2026, to Delivery Order 2 to the BioThrax IDIQ Contract..
FiledFormExhibitDescription
2026-09-018-K10.1Modification No. 21, effective August 18, 2026 to the BARDA AV7909 Contract
2026-08-0610-Q10.9Modification No. 15, effective June 26, 2026, to the ACAM2000 Contract (incorporated by reference to Exhibit 99.1 to the Company’s Current Report on Form 8-K, filed on June 29, 2026)
2026-08-0610-Q10.8Modification No. 2, effective May 18, 2026, to the BioThrax IDIQ Contract.
2026-08-0610-Q10.7Modification No. 2, effective March 4, 2026, to Delivery Order 2 to the BioThrax IDIQ Contract.
2026-08-0610-Q10.6Modification No. 1, effective January 26, 2026, to Delivery Order 2 to the BioThrax IDIQ Contract.
2026-08-0610-Q10.5Delivery Order 2, effective January 7, 2026, to the BioThrax IDIQ Contract.
2026-08-0610-Q10.4Modification No. 1, effective April 23, 2024, to the BioThrax IDIQ Contract.
2026-08-0610-Q10.3Modification No. 6, effective September 17, 2025, to Delivery Order 1 to the BioThrax IDIQ Contract.
2026-08-0610-Q10.2Modification No. 5, effective March 13, 2025, to the Delivery Order 1 to the BioThrax IDIQ Contract.
2026-08-0610-Q10.1Modification No. 4, effective January 24, 2025, to the Delivery Order 1 to the BioThrax IDIQ Contract.
2026-04-308-K10.1Emergent BioSolutions Inc. Amended and Restated Stock Incentive Plan
2026-04-178-K10.2Amendment No. 1 to Credit Agreement dated April 16, 2026, by and among Emergent BioSolutions Inc. and the other borrowers party thereto, the lenders party thereto and Wells Fargo Bank, National Association, as administrative agent†
2026-04-178-K10.1Credit Agreement dated April 16, 2026, by and among Emergent BioSolutions Inc., the guarantors party thereto, the lenders party thereto and OrbiMed Royalty & Credit Opportunity V LP, as administrative agent†

Similar stocks

Stock NameCountryMarket CapPE Ratio
ENANTA PHARMACEUTICALS INC (ENTA)United States$0.349B-6.72
Larimar Therapeutics, Inc. (LRMR)United States$0.344B-1.83
Vogenx, Inc. (VOGX)United States$0.355B
Benitec Biopharma Inc. (BNTC)United States$0.337B-10.08
BioAge Labs, Inc. (BIOA)United States$0.333B-11.88
BridgeBio Oncology Therapeutics, Inc. (BBOT)United States$0.320B-3.35
Evommune, Inc. (EVMN)United States$0.320B-5.10
Prelude Therapeutics Inc (PRLD)United States$0.318B-7.01
ABEONA THERAPEUTICS INC. (ABEO)United States$0.312B-5.63
Rezolute, Inc. (RZLT)United States$0.382B-6.45